Preliminary result of a new protocol for the active immunotherapy of acute lymphoblastic leukaemia: inhibition of the immunotherapeutic effect by Vincristine or Adamantadine.
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000547:Amantadine / Q000008:administration & dosage*; D001215:Asparaginase / Q000008:administration & dosage; D001500:BCG Vaccine; D002648:Child; D002675:Child, Preschool; D003561:Cytarabine / Q000008:administration & dosage; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage; D007110:Immunity, Active; D007116:Immunization, Passive; D007167:Immunotherapy; D007223:Infant; D002955:Leucovorin / Q000008:administration & dosage; D007945:Leukemia, Lymphoid / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D015122:Mercaptopurine / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D011882:Radiotherapy, High-Energy; D012075:Remission, Spontaneous; D014750:Vincristine / Q000008:administration & dosage*
D001500:BCG Vaccine; D003561:Cytarabine; D014750:Vincristine; D000547:Amantadine; D015122:Mercaptopurine; D001215:Asparaginase; D002955:Leucovorin; D011241:Prednisone; D006854:Hydrocortisone; D008727:Methotrexate